Meghana Keshavan, STAT

Meghana Keshavan


Cleveland, OH, United States

Contact Meghana

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Unknown
  • STAT
  • Scientific American
  • The Boston Globe
  • Fox News

Past articles by Meghana:

Virtual drug screening identifies possible new antidepressants in LSD-like molecules

What’s a hallucinogen without the hallucinations? Perhaps a potent and fast-acting antidepressant, according to a new study based on virtual drug screening. → Read More

What ‘Beans’ taught her parents about cancer and the need for research

STAT spoke with Andrew Kaczynski about his family’s journey — and what he believes can be done to help others dealing with pediatric cancer. → Read More

Study offers new clues for treating brain cancer in children

Molecular details of 218 pediatric brain tumors reveals connections between certain proteins and a patient's prognosis. → Read More

A MacArthur 'genius' will likely use his grant to support his wife’s work

Damien Fair, a University of Minnesota neuroscientist, received the honor, but shares a rare and touching research symbiosis with his wife. → Read More

Experimental ALS drug, dreamed up in a dorm room, offers patients hope

Patients who took the medication retained a higher level of certain motor functions than those given a placebo, researchers say. → Read More

Research sheds light on sex imbalances in schizophrenia, lupus

A new paper in Nature helps unravel why some conditions might manifest themselves more commonly, or intensely, in one sex over another. → Read More

Drug is effective against graft-versus-host disease, data show

A new study confirms what many oncologists have known, anecdotally, for years: that a chemotherapy drug can dramatically improve the odds of some patients. → Read More

At epicenter of pandemic, Seattle nurse treats two patients at a time

"Some of my colleagues are nervous about working with Covid-19 patients, but a lot of people are just kind of happy ... to help out," the ICU nurse said. → Read More

2019 in limericks: The highs and lows from the life sciences

To mark the highs and lows of 2019, STAT is continuing its annual tradition: the life-science year in review in limericks. → Read More

Consumer DNA Tests Negate Sperm Bank Donor Anonymity

Companies like 23andMe and have made it impossible for sperm banks to keep donors’ identities secret → Read More

Q&A on Alzheimer's research: What's gone wrong and what's going right?

STAT sat down with Dr. Richard Hodes, director of the NIH’s National Institute on Aging, at the Alzheimer’s Association International Conference. → Read More

A psychedelics evangelist tries to turn magic mushrooms into medicine

Christian Angermayer, a German financier, is one of the driving forces behind the movement to turn psychoactive substances into drugs for mental illness. → Read More

Development of new antibiotics will require new incentives, experts say

Currently the private sector is largely unwilling to take on the financial risk of developing new antiotiics, even though they are desperately needed. → Read More

Probiotics are touted as good for the gut. They may be trouble for the immune system

Researchers found that melanoma patients were 70 percent less likely to respond to cancer immunotherapy if they were also taking probiotic supplements. → Read More

With one manufacturer and little money to be made, supplies of a critical cancer drug are dwindling

Companies have little incentive to make a drug like BCG, which is remarkably effective at treating bladder cancer but hardly lucrative. → Read More

2018 in limericks: The highs and lows from the life sciences

To mark the highs and lows of 2018, STAT is continuing its annual tradition: the life-science year in review in limericks. → Read More

‘A loss for the rest of us’: An FDA approval is a boon for a drug maker, but could come at a major cost for patients

A Florida-based drug maker now has the ability to charge a premium on a drug that has come free or dirt cheap for many patients for decades. → Read More

Single-cell sequencing is opening up new avenues for potential treatments

By quickly analyzing thousands — even millions — of cells, it’s now possible to visualize the specific cellular culprits for any given disease. → Read More

A new study offers a glimpse into the genetics of same-sex attraction

A massive genetic study touches on the question of whether it’s worthwhile, or even ethical, to study the genetics of sexual attraction in the first place. → Read More

Saving Mila: How a tailor-made therapy, developed in a flash, may have halted a young girl’s rare disease

Thanks to a remarkable effort on the part of Boston Children’s Hospital scientists, regulators, and the family of a girl, an experimental therapy was developed in record time. → Read More